A landmark auction appointment for a one-of-a-kind T-Rex leather handbag drove BSF Enterprise (LSE:BSFA) to the top of the health and biotech tape, while clinical and regulatory progress across the sector kept deal flow active. Elsewhere, an analyst flag on hVIVO (AIM:HVO) served as a reminder that contract momentum alone does not yet signal a full market recovery.
BSF Enterprise to auction world's first T-Rex leather handbag at Drouot
BSF Enterprise (AIM:BSFA) has appointed Paris auction house Giquello SAS to sell the T-Rex Leather™ Enfin Leve handbag, billed as the world's first handbag made from lab-grown T-Rex leather, at the Drouot auction rooms on 11 June. The commission was secured through BSF's subsidiary Lab-Grown Leather, and the one-off nature of the piece positions it as both a luxury and a scientific artefact. The announcement sent shares up 15.14% to 2.015p, making it the sharpest move in the sector on the day.
genedrive MT-RNR1 test transitions to routine NHS clinical use
genedrive (AIM:GDR) confirmed that its Genedrive (AIM:GDR)® MT-RNR1 ID kit has moved from pilot to Business as Usual clinical service at University Hospitals Sussex NHS Foundation Trust, effective 1 May. The transition marks a meaningful step in the commercial embedding of the point-of-care genetic test, which screens for a variant associated with antibiotic-induced hearing loss. Shares slipped 4.68% to 0.9055p on the day despite the operational milestone.
ImmuPharma engages tranScrip to advance Kapiglucagon towards FDA
ImmuPharma (AIM:IMM) has brought in specialist regulatory consultancy tranScrip to prepare a pre-IND meeting with the FDA and map out a 505(b)(2) regulatory pathway for Kapiglucagon, its diabetes prodrug candidate. The 505(b)(2) route allows the company to draw on existing safety and efficacy data, potentially reducing the cost and timeline of development. Shares eased 1.57% to 4.075p.
Creo Medical's SpydrBlade Flex used in pioneering BEAM bariatric procedures
Creo Medical Group (AIM:CREO) saw its SpydrBlade™ Flex device used to perform two bariatric endoscopic antral myotomy, BEAM, procedures, with the cases presented at the Frontiers in Endoscopic Surgery 2026 conference. The procedures were carried out by a US pioneer in the technique, adding clinical credibility to the device's application in weight-management endoscopy. Shares were broadly flat, off 0.99% at 12.5p.
Panmure Liberum holds hVIVO at Hold, flags recovery still unproven
hVIVO (AIM:HVO) remained under scrutiny after Panmure Liberum analyst Seb Jantet maintained a Hold rating and an unchanged price target of 10p. The broker acknowledged that recent contract wins underpin current forecasts but argued they do not yet demonstrate a broad recovery in the human challenge trial market, leaving the company with more to prove before the investment case strengthens. Shares fell 1.37% to 7.2p.
